Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accumulated Expenses (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Accumulated Expenses for 8 consecutive years, with $63.5 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Expenses fell 6.31% to $63.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $63.5 million, a 6.31% decrease, with the full-year FY2024 number at $63.5 million, down 6.31% from a year prior.
  • Accumulated Expenses was $63.5 million for Q4 2024 at Akebia Therapeutics, down from $67.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $144.7 million in Q3 2021 to a low of $51.1 million in Q1 2023.
  • A 5-year average of $95.3 million and a median of $95.0 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 13185.21% in 2020, then tumbled 55.29% in 2023.
  • Akebia Therapeutics' Accumulated Expenses stood at $130.6 million in 2020, then fell by 16.54% to $109.0 million in 2021, then tumbled by 30.49% to $75.8 million in 2022, then dropped by 10.61% to $67.7 million in 2023, then fell by 6.31% to $63.5 million in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Accumulated Expenses are $63.5 million (Q4 2024), $67.7 million (Q4 2023), and $62.7 million (Q3 2023).